NervGen Pharma Corp. NGENF
3.95 USD 0.00 (+0.00%)
Mar 11, 2026, 9:30 AM EDT
3.90 Day range 4.09
1.50 52-week range 6.30
- YTD
- -29.46%
- 1 year
- +97.50%
- Market cap
- 312.89M
- EPS (ttm)
- -0.26
- P/E ratio
- -15.19
- YTD return
- -29.46%
- 1-year return
- +97.50%
- Volume
- 88.33K
- Avg volume
- 157.91K
- Open
- 4.07
- Previous close
- 3.95
- Day's range
- 3.90 – 4.09
- 52-week range
- 1.50 – 6.30
No chart data for this range yet.
News
NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium 
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury 
NervGen Pharma Begins Trading on Nasdaq Today 
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS 
NervGen Pharma Announces Proposed Amendment to Warrants 
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates 
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury 
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development 
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development 
NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders
Your note
Sign in to keep a note on NGENF — it syncs with the Stock Master app.